Rethinking recommendations for screening for depression in primary care - 21/06/12
Doi : 10.1503/cmaj.111035
Brett D. Thombs, PhD a, ⁎ 
, James C. Coyne, PhD b, c, Pim Cuijpers, PhD d, Peter de Jonge, PhD e, Simon Gilbody, DPhil f, John P.A. Ioannidis, MD DSc g, h, i, Blair T. Johnson, PhD j, Scott B. Patten MD, PhD k, Erick H. Turner, MD l, Roy C. Ziegelstein, MD m
, James C. Coyne, PhD b, c, Pim Cuijpers, PhD d, Peter de Jonge, PhD e, Simon Gilbody, DPhil f, John P.A. Ioannidis, MD DSc g, h, i, Blair T. Johnson, PhD j, Scott B. Patten MD, PhD k, Erick H. Turner, MD l, Roy C. Ziegelstein, MD m a Department of Psychiatry; Medicine; Epidemiology, Biostatistics, and Occupational Health; and the School of Nursing, McGill University and Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Que
b Department of Psychiatry; Medicine; Epidemiology, Biostatistics, and Occupational Health; Behavioral Oncology Program, Abramson Cancer Center and Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pa
c Department of Psychiatry; Medicine; Epidemiology, Biostatistics, and Occupational Health; Health Psychology Section, Department of Health Sciences, University Medical Center Groningen, University of Groningen, the Netherland
d Department of Clinical Psychology and EMGO Institute, Vrije Universiteit, Amsterdam, the Netherlands
e Interdisciplinary Center for Psychiatric Epidemiology, University Medical Center, University of Groningen, Groningen, the Netherlands
f Psychological Medicine and Health Services Research, Hull York Medical School and Department of Health Sciences, University of York, York, UK
g Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, and Biomedical Research Institute, Foundation for Research and Technology–Hellas, Ioannina, Greece
h Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Department of Medicine, Tufts University School of Medicine, Boston, Mass.
i Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, Calif.
j Department of Psychology and Center for Health, Intervention and Prevention, University of Connecticut, Storrs, Conn.
k Department of Psychiatry and Community Health Sciences, University of Calgary, Calgary, Alta.
l Department of Psychiatry, Oregon Health and Science University and Portland Veterans Affairs Medical Center, Portland, Ore.
m Department of Medicine (Ziegelstein), Johns Hopkins University School of Medicine, Baltimore, Md.
* Correspondence to: Dr. Brett D. Thombs
Contributors: Dr. Thombs drafted the article. All of the authors participated in preliminary discussions to develop the concepts described in the article, agreed upon an outline for the article, revised the article critically for intellectual content and approved the final version of the manuscript submitted for publication.
Plan
| Competing interests: Blair Johnson is a consultant for the American College of Sports Medicine. Scott Patten is a consultant for Cipher Pharmaceuticals and Servier Canada; he has provided expert testimony for Cipher Pharmaceuticals concerning safety provisions during a clinical trial for an acne medication associated with adverse psychiatric effects; he has received grant funding from Servier Canada to research the use of benziodiazepines and changes in weight associated with treatment with antidepressant medications; and he has received speaker fees from Lundbeck. No other competing interests were declared. This article has been peer reviewed. Funding: Funds from a Meetings, Planning and Dissemination grant from the Canadian Institutes of Health Research (CIHR; grant no. MIN 92725) were used for a meeting of the author group, which led to the preparation of this article. Dr. Thombs is supported by a New Investigator Award from the CIHR and an Établissement de Jeunes Chercheurs award from the Fonds de la Recherche en Santé Québec. Dr. Patten is a Senior Health Scholar with Alberta Innovates, Health Solutions. Dr. Ziegelstein is supported by the National Center for Complementary and Alternative Medicine (grant no. R24AT004641) and the Miller Family Scholar Program of the Johns Hopkins Center for Innovative Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Complementary and Alternative Medicine or the National Institutes of Health. |
© 2012
Canadian Medical Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 184 - N° 4
P. 413-418 - mars 2012 Retour au numéro
Article précédent
- Acupuncture for migraine prophylaxis: a randomized controlled trial
- Ying Li, Hui Zheng, Claudia M. Witt, Stephanie Roll, Shu-guang Yu, Jie Yan, Guo-jie Sun, Ling Zhao, Wen-jing Huang, Xiao-rong Chang, Hong-xing Zhang, Lei Lan, Ran Zou, Fan-rong Liang, De-jun Wang
- Recurrent exercise-induced rhabdomyolysis
- Fady Hannah-Shmouni, Kevin McLeod, Sandra Sirrs
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?